Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
|Videos|November 4, 2021
Emerging Psychedelic Therapies
Author(s)Alexander Somjen
Here's why psychedelics might be a valuable addition to mental health treatment.
Advertisement
Alexander Somjen discusses the fragmented psychedelic industry, regulatory frameworks, and potential commercial success.
Alexander Somjen is the CEO and Director of
Advertisement
Related to this article
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
3
Interventional Options for TRD: ECT, TMS, and Esketamine
4
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
5